ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1084

Statin Use in Patients with CKD (Nondialysis) in Ambulatory Care: A Quality Improvement Project at a Rural Community Hospital

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Hassan, Waleed, North Mississippi Medical Center, Tupelo, Mississippi, United States
  • Rayford, Vernon, North Mississippi Medical Center, Tupelo, Mississippi, United States

Group or Team Name

  • North Mississippi Medical Center.
Background

Chronic kidney disease (CKD) is a known risk factor for cardiovascular disease (CVD). Statins have been shown to reduce CVD risk in CKD (Non-Dialysis) with or without diabetes.

Methods

This is a quality improvement project at North Mississippi Medical Center as a retrospective analysis of 304,575 observations in a total of 178,722 patients. Data were extracted from an office or wellness visit at any Epic clinic between 7/1/2021 and 7/1/2022. CKD diagnosis was made based on an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 for > 3 months. The estimated GFR was calculated by the CKD-EPI creatinine equation (2021). The 10-year atherosclerotic cardiovascular (ASCVD) risk was calculated using Pooled Cohort Equations, the risk was categorized as <5%, 5-7.4%, and ≥7.5-10% in patients who met CKD criteria.

Results

Out of the total observations of 119,557 representing 43,557 patients, 8538 patients (20%) met the CKD criteria by eGFR. Demographic characteristics are shown in table 1. For patients with CKD (Non-Dialysis) and diabetes with a 10-year ASCVD risk of ≥7.5-10%, the majority (~75%) were on statins versus 18% being not on statins (figure1). Differently, only 65 % of CKD patients without diabetes with a 10-year ASCVD risk of ≥7.5-10% were found to be taking statins versus 25% not on statins (figure2).

Conclusion

Statin is an underused protective shield in patients with CKD (Non-Dialysis) in the ambulatory setting.